Calcium Chloride

證據等級: L5

預測適應症: 10 個

Calcium Chloride: From Calcium Supplementation to Dyspepsia

One-Sentence Summary

Calcium chloride (CaCl₂) is an inorganic calcium salt clinically used for hypocalcaemia treatment and cardiac resuscitation, with no registered indications in Singapore. The TxGNN model predicts potential efficacy for Dyspepsia with a confidence score of 97.47%, supported by 10 retrieved clinical trials and 5 publications — however, none of these directly test CaCl₂ for this indication, and the underlying mechanistic rationale is considered weak and potentially contrary to safe clinical use.

Quick Overview

Item	Content
Original Indication	No approved indication recorded in Singapore regulatory data
Predicted New Indication	Dyspepsia
TxGNN Prediction Score	97.47%
Evidence Level	L5
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for calcium chloride is not available in the current Evidence Pack. Based on established pharmacology, CaCl₂ is an electrolyte that dissociates in aqueous solution to provide calcium (Ca²⁺) and chloride (Cl⁻) ions. Its proven clinical applications include emergency treatment of hypocalcaemia, cardiac resuscitation, reversal of calcium channel blocker toxicity, and correction of hyperkalemic cardiac arrhythmias.

Dyspepsia is characterised by upper gastrointestinal discomfort — including bloating, early satiety, epigastric pain, and nausea. The TxGNN model may have identified calcium chloride as a candidate because calcium-based compounds, particularly calcium carbonate (CaCO₃), are widely used antacids. CaCO₃ neutralises gastric acid through its alkaline buffering properties, thereby relieving dyspeptic symptoms. However, CaCl₂ is chemically and functionally distinct: it does not possess alkaline buffering capacity and cannot neutralise gastric acid in the same manner as carbonate-based antacids.

⚠️ Mechanistic Warning: Rather than being a treatment candidate, concentrated CaCl₂ is corrosive to the gastric mucosa. A published case report documents severe corrosive gastritis, gastric stenosis, and perforation following accidental ingestion of CaCl₂ (PMID 34897144). Additionally, a 1966 veterinary publication (PMID 6012101) describes the use of Locke-Ringer's solution — a multi-electrolyte mixture containing CaCl₂ among other salts — for calf dyspepsia, representing the sole indirect historical connection between calcium and this indication; this does not support CaCl₂ alone as a therapeutic agent. The model prediction is likely a false positive driven by superficial chemical similarity between calcium chloride and calcium carbonate. The predicted direction is mechanistically unsupported and potentially harmful.

Clinical Trial Evidence

None of the 10 clinical trials retrieved for dyspepsia directly test calcium chloride. They are presented below for disease landscape context only.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06320379	N/A	Recruiting	64	Assesses the effect of an undisclosed dietary supplement on quality of life and digestion in adults with functional dyspepsia — disease-relevant, but does not test CaCl₂
NCT01149369	Phase 2	Completed	126	Aprepitant (NK1 receptor antagonist) for 4 weeks in patients with chronic nausea and vomiting of presumed gastric origin — demonstrates NK1 pathway as a dyspepsia/gastroparesis target; does not involve CaCl₂
NCT05346302	Early Phase 1	Completed	249	Biomarker, facial, and audio data collection to predict early infection via early warning scores — immunisation study with no relevance to dyspepsia or CaCl₂
NCT05111912	Phase 2	Completed	206	XW003 (once-weekly GLP-1 analogue) vs. liraglutide 3 mg for obesity management — metabolic disease trial with no connection to dyspepsia treatment or CaCl₂
NCT01725126	Phase 2	Completed	53	GSK2890457 first-in-human safety and tolerability study in healthy volunteers and T2DM patients — no specific connection to dyspepsia or CaCl₂
NCT02202161	Phase 2	Completed	70	GSK2330672 (bile acid transport inhibitor) safety/PK/PD vs. sitagliptin combined with metformin in T2DM — no connection to dyspepsia or CaCl₂
NCT01929863	Phase 2	Completed	16	GSK2330672 crossover study in T2DM on metformin — confirms bile acid inhibitor safety profile; no connection to dyspepsia or CaCl₂
NCT05258513	N/A	Completed	83	Geranylgeraniol (GG) supplementation on sexual health function in males and females — no connection to dyspepsia or CaCl₂
NCT05813548	N/A	Completed	42	App-based lifestyle change programme for body composition in women aged 30–55 — no connection to dyspepsia or CaCl₂
NCT03360435	N/A	Completed	99	Transdermal vitamin and mineral patch absorption in post-bariatric surgery patients — evaluates micronutrient deficiency correction, not dyspepsia treatment; no connection to CaCl₂

Literature Evidence

None of the 5 publications retrieved directly demonstrate CaCl₂ efficacy in human dyspepsia.

PMID	Year	Type	Journal	Key Findings
40317635	2025	Animal/Mechanistic	Neurogastroenterology and Motility	Amitriptyline + domperidone combination suppresses FD-like behaviour in rats via central and peripheral mechanisms — provides insight into FD pathophysiology but has no CaCl₂ involvement
35319360	2022	Formulation Study	Current Drug Metabolism	Aceclofenac-loaded microspheres designed to reduce NSAID-induced gastrointestinal side effects including dyspepsia — highlights GI protection strategies; no CaCl₂ connection
31185476	2020	In Vitro	Digestion	Traditional herbal formula Banhasasim-Tang modulates interstitial cells of Cajal via M3 muscarinic and 5-HT3 receptors in murine small intestine — GI motility mechanism study with no CaCl₂ connection
5103465	1971	Historical/Case Series	Veterinariia	Historical veterinary report on preparation and use of multi-compound drug mixtures for dyspepsia — calcium salts may have been included as components; insufficient detail for modern evidence assessment
6012101	1966	Animal/Veterinary	Veterinariia	Locke-Ringer's solution (a multi-electrolyte mixture containing CaCl₂, NaCl, KCl, NaHCO₃, and glucose) used for dyspepsia in calves — the sole indirect historical connection between calcium and dyspepsia treatment; evidence is veterinary, approximately 60 years old, and attributes therapeutic effect to the combined electrolyte solution rather than CaCl₂ specifically

Singapore Market Information

Calcium chloride (DB01164) has no products registered with the Health Sciences Authority (HSA) of Singapore. No license or approved indication data is available for this market.

Safety Considerations

Please refer to the package insert for safety information.

Important findings identified during predicted indication analysis:

Gastric Corrosivity Risk: A published case report (PMID 34897144) documents severe corrosive gastritis, gastric stenosis, and gastric penetration following accidental CaCl₂ ingestion in a human patient, accompanied by marked hypercalcaemia (calcium 18.6 mg/dL). This finding directly contradicts any proposed oral use of CaCl₂ for gastrointestinal indications.
Calcium-Alkali Syndrome (TxGNN Rank #2 Prediction — Safety Alert): The model's second-ranked prediction is calcium-alkali syndrome. This is a condition that CaCl₂ can cause, not treat. Excessive calcium supplementation combined with alkaline substances leads to the triad of hypercalcaemia, metabolic alkalosis, and acute kidney injury — this is a recognised adverse effect profile of calcium-based compounds and represents a directional error in the model output that requires attention.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction of dyspepsia for calcium chloride achieves a high confidence score (97.47%) but rests on model inference alone (L5), with zero clinical trials or publications directly testing CaCl₂ for this indication. More critically, mechanistic analysis reveals this prediction is very likely a false positive — CaCl₂ lacks the alkaline buffering properties of carbonate antacids, has documented gastric corrosivity, and may cause rather than treat calcium-related gastrointestinal conditions. Proceeding with this repurposing hypothesis carries a meaningful patient safety risk.

To proceed, the following is needed:

Obtain complete mechanism of action (MOA) data from DrugBank (identified data gap DG002) to determine whether any indirect calcium-signalling pathway could plausibly support the prediction
Address the Singapore regulatory data gap (DG001) by retrieving the official package insert warnings and contraindications from the HSA or equivalent authority
Conduct a focused investigation of the stomach disease (rank 6) prediction, which represents the most scientifically credible mechanistic hypothesis in this pack: two rat studies (PMID 1638681, PMID 2805233) show oral CaCl₂ inhibits NaCl-induced pyloric mucosal DNA replication and suppresses MNNG-induced gastric carcinogenesis — a potential chemopreventive mechanism that deserves a dedicated preclinical research question
Clarify formulation context before any further development: intravenous CaCl₂ (electrolyte correction) and oral/luminal CaCl₂ carry fundamentally different safety profiles and should not be conflated in repurposing analyses
If a gastrointestinal indication involving calcium is to be explored, calcium carbonate or other alkaline calcium salts are the pharmacologically appropriate candidates, not calcium chloride
Consider implementing pharmacological subtype disambiguation in the TxGNN pipeline to prevent CaCl₂ from inheriting prediction signals from structurally and functionally distinct calcium compounds
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.